|
Gene: ACADVL |
Gene summary for ACADVL |
Gene summary. |
Gene information | Species | Human | Gene symbol | ACADVL | Gene ID | 37 |
Gene name | acyl-CoA dehydrogenase very long chain | |
Gene Alias | ACAD6 | |
Cytomap | 17p13.1 | |
Gene Type | protein-coding | GO ID | GO:0001659 | UniProtAcc | P49748 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
37 | ACADVL | GSM4909281 | Human | Breast | IDC | 1.48e-14 | -5.38e-01 | 0.21 |
37 | ACADVL | GSM4909282 | Human | Breast | IDC | 6.91e-27 | -6.48e-01 | -0.0288 |
37 | ACADVL | GSM4909285 | Human | Breast | IDC | 2.82e-11 | -4.31e-01 | 0.21 |
37 | ACADVL | GSM4909286 | Human | Breast | IDC | 8.44e-34 | -7.11e-01 | 0.1081 |
37 | ACADVL | GSM4909287 | Human | Breast | IDC | 1.15e-21 | -6.15e-01 | 0.2057 |
37 | ACADVL | GSM4909288 | Human | Breast | IDC | 7.28e-08 | -6.27e-01 | 0.0988 |
37 | ACADVL | GSM4909290 | Human | Breast | IDC | 9.24e-20 | -6.51e-01 | 0.2096 |
37 | ACADVL | GSM4909291 | Human | Breast | IDC | 8.17e-13 | -6.02e-01 | 0.1753 |
37 | ACADVL | GSM4909293 | Human | Breast | IDC | 6.07e-17 | -5.43e-01 | 0.1581 |
37 | ACADVL | GSM4909294 | Human | Breast | IDC | 1.27e-26 | -6.72e-01 | 0.2022 |
37 | ACADVL | GSM4909295 | Human | Breast | IDC | 7.96e-05 | -4.69e-01 | 0.0898 |
37 | ACADVL | GSM4909296 | Human | Breast | IDC | 1.63e-38 | -7.32e-01 | 0.1524 |
37 | ACADVL | GSM4909297 | Human | Breast | IDC | 9.42e-22 | -3.12e-01 | 0.1517 |
37 | ACADVL | GSM4909298 | Human | Breast | IDC | 6.95e-08 | -3.59e-01 | 0.1551 |
37 | ACADVL | GSM4909301 | Human | Breast | IDC | 1.11e-20 | -6.29e-01 | 0.1577 |
37 | ACADVL | GSM4909302 | Human | Breast | IDC | 6.60e-07 | -3.80e-01 | 0.1545 |
37 | ACADVL | GSM4909307 | Human | Breast | IDC | 3.13e-22 | -6.49e-01 | 0.1569 |
37 | ACADVL | GSM4909308 | Human | Breast | IDC | 2.92e-15 | -5.10e-01 | 0.158 |
37 | ACADVL | GSM4909309 | Human | Breast | IDC | 2.25e-13 | -5.02e-01 | 0.0483 |
37 | ACADVL | GSM4909311 | Human | Breast | IDC | 5.38e-47 | -6.40e-01 | 0.1534 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00090628 | Esophagus | ESCC | fatty acid catabolic process | 66/8552 | 100/18723 | 3.21e-05 | 2.66e-04 | 66 |
GO:00066318 | Esophagus | ESCC | fatty acid metabolic process | 217/8552 | 390/18723 | 4.21e-05 | 3.39e-04 | 217 |
GO:00066358 | Esophagus | ESCC | fatty acid beta-oxidation | 50/8552 | 74/18723 | 1.16e-04 | 8.04e-04 | 50 |
GO:000926619 | Esophagus | ESCC | response to temperature stimulus | 106/8552 | 178/18723 | 1.30e-04 | 8.84e-04 | 106 |
GO:00463948 | Esophagus | ESCC | carboxylic acid biosynthetic process | 175/8552 | 314/18723 | 1.98e-04 | 1.26e-03 | 175 |
GO:00160538 | Esophagus | ESCC | organic acid biosynthetic process | 175/8552 | 316/18723 | 3.04e-04 | 1.82e-03 | 175 |
GO:00620129 | Esophagus | ESCC | regulation of small molecule metabolic process | 184/8552 | 334/18723 | 3.11e-04 | 1.85e-03 | 184 |
GO:00723297 | Esophagus | ESCC | monocarboxylic acid catabolic process | 74/8552 | 122/18723 | 6.03e-04 | 3.27e-03 | 74 |
GO:19026524 | Esophagus | ESCC | secondary alcohol metabolic process | 87/8552 | 147/18723 | 6.58e-04 | 3.50e-03 | 87 |
GO:00421805 | Esophagus | ESCC | cellular ketone metabolic process | 120/8552 | 211/18723 | 6.70e-04 | 3.55e-03 | 120 |
GO:00442427 | Esophagus | ESCC | cellular lipid catabolic process | 121/8552 | 214/18723 | 8.63e-04 | 4.43e-03 | 121 |
GO:00442827 | Esophagus | ESCC | small molecule catabolic process | 201/8552 | 376/18723 | 1.35e-03 | 6.41e-03 | 201 |
GO:00082034 | Esophagus | ESCC | cholesterol metabolic process | 79/8552 | 137/18723 | 3.11e-03 | 1.29e-02 | 79 |
GO:00161254 | Esophagus | ESCC | sterol metabolic process | 86/8552 | 152/18723 | 4.37e-03 | 1.73e-02 | 86 |
GO:00302586 | Esophagus | ESCC | lipid modification | 116/8552 | 212/18723 | 4.90e-03 | 1.89e-02 | 116 |
GO:00160427 | Esophagus | ESCC | lipid catabolic process | 168/8552 | 320/18723 | 7.97e-03 | 2.84e-02 | 168 |
GO:00192168 | Esophagus | ESCC | regulation of lipid metabolic process | 172/8552 | 331/18723 | 1.20e-02 | 4.02e-02 | 172 |
GO:000609112 | Liver | Cirrhotic | generation of precursor metabolites and energy | 238/4634 | 490/18723 | 6.85e-31 | 1.07e-27 | 238 |
GO:001598012 | Liver | Cirrhotic | energy derivation by oxidation of organic compounds | 154/4634 | 318/18723 | 3.11e-20 | 8.87e-18 | 154 |
GO:000820211 | Liver | Cirrhotic | steroid metabolic process | 143/4634 | 319/18723 | 2.79e-15 | 3.18e-13 | 143 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa00071 | Colorectum | AD | Fatty acid degradation | 20/2092 | 43/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 20 |
hsa000711 | Colorectum | AD | Fatty acid degradation | 20/2092 | 43/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 20 |
hsa000712 | Colorectum | SER | Fatty acid degradation | 15/1580 | 43/8465 | 8.60e-03 | 4.26e-02 | 3.09e-02 | 15 |
hsa000713 | Colorectum | SER | Fatty acid degradation | 15/1580 | 43/8465 | 8.60e-03 | 4.26e-02 | 3.09e-02 | 15 |
hsa000714 | Colorectum | MSS | Fatty acid degradation | 17/1875 | 43/8465 | 7.50e-03 | 2.86e-02 | 1.75e-02 | 17 |
hsa000715 | Colorectum | MSS | Fatty acid degradation | 17/1875 | 43/8465 | 7.50e-03 | 2.86e-02 | 1.75e-02 | 17 |
hsa000716 | Colorectum | FAP | Fatty acid degradation | 15/1404 | 43/8465 | 2.73e-03 | 1.23e-02 | 7.50e-03 | 15 |
hsa000717 | Colorectum | FAP | Fatty acid degradation | 15/1404 | 43/8465 | 2.73e-03 | 1.23e-02 | 7.50e-03 | 15 |
hsa012129 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
hsa0121214 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
hsa0007121 | Liver | Cirrhotic | Fatty acid degradation | 29/2530 | 43/8465 | 3.87e-07 | 4.95e-06 | 3.05e-06 | 29 |
hsa012122 | Liver | Cirrhotic | Fatty acid metabolism | 32/2530 | 57/8465 | 3.12e-05 | 2.47e-04 | 1.52e-04 | 32 |
hsa04936 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
hsa0007131 | Liver | Cirrhotic | Fatty acid degradation | 29/2530 | 43/8465 | 3.87e-07 | 4.95e-06 | 3.05e-06 | 29 |
hsa012123 | Liver | Cirrhotic | Fatty acid metabolism | 32/2530 | 57/8465 | 3.12e-05 | 2.47e-04 | 1.52e-04 | 32 |
hsa049361 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
hsa012124 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
hsa0007141 | Liver | HCC | Fatty acid degradation | 33/4020 | 43/8465 | 8.41e-05 | 4.27e-04 | 2.37e-04 | 33 |
hsa049362 | Liver | HCC | Alcoholic liver disease | 89/4020 | 142/8465 | 1.73e-04 | 8.53e-04 | 4.75e-04 | 89 |
hsa012125 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ACADVL | SNV | Missense_Mutation | c.232N>T | p.His78Tyr | p.H78Y | P49748 | protein_coding | tolerated(1) | benign(0.093) | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD | |
ACADVL | SNV | Missense_Mutation | rs794727111 | c.1435C>T | p.Arg479Cys | p.R479C | P49748 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ACADVL | SNV | Missense_Mutation | c.874G>C | p.Asp292His | p.D292H | P49748 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
ACADVL | SNV | Missense_Mutation | rs762653370 | c.1021N>T | p.Pro341Ser | p.P341S | P49748 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ACADVL | SNV | Missense_Mutation | novel | c.1619N>A | p.Ser540Asn | p.S540N | P49748 | protein_coding | tolerated(0.23) | benign(0.014) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ACADVL | SNV | Missense_Mutation | c.1937N>G | p.Ser646Cys | p.S646C | P49748 | protein_coding | deleterious(0.03) | benign(0.056) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ACADVL | SNV | Missense_Mutation | novel | c.28N>A | p.Gly10Arg | p.G10R | P49748 | protein_coding | tolerated_low_confidence(0.75) | unknown(0) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ACADVL | SNV | Missense_Mutation | c.778T>C | p.Cys260Arg | p.C260R | P49748 | protein_coding | deleterious(0.04) | possibly_damaging(0.89) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ACADVL | SNV | Missense_Mutation | c.673N>A | p.Leu225Ile | p.L225I | P49748 | protein_coding | deleterious(0.01) | probably_damaging(0.971) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ACADVL | deletion | Frame_Shift_Del | novel | c.1450_1451delNN | p.Phe484Ter | p.F484* | P49748 | protein_coding | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |